Penumbra, Inc. Earnings Recaps
Q3 2025
Nov 7, 2025
Penumbra reported strong third-quarter results for 2025, achieving $354.7 million in revenue driven by robust growth across its U.S. thrombectomy and embolization franchises, highlighting its competitive positioning and successful product innovation.
Key takeaways
- Total revenue increased by 17.8% year-over-year, with U.S. revenue growing 21.5% to $275 million.
- The VTE franchise achieved remarkable 34% year-over-year growth, affirming its market leadership.
- Gross margin expanded to 67.8%, with operating income at $48.8 million (13.8% of revenue), and future margins are projected to exceed 70%.
- FDA clearance for breakthrough products Lightning Bolt 16 and Lightning Flash 3.0 enhances Penumbra's advanced CAVT device portfolio.
- The integration of a dedicated embolization sales team has resulted in a 21.2% sequential revenue increase in this segment.